- Home
- MOGU vs NCEL Comparison
MOGU vs NCEL Comparison
Compare MOGU & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOGU | NCEL |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | Switzerland |
| Employees | N/A | 4 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 17.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MOGU | NCEL |
|---|---|---|
| Price | $1.96 | $3.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 28.3K |
| Earning Date | 01-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $1.83 |
| 52 Week High | $8.10 | $5.12 |
Technical Indicators
Market Signals| Indicator | MOGU | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 51.75 |
| Support Level | $1.85 | $2.95 |
| Resistance Level | $2.57 | $3.62 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.95 | 56.66 |
Price Performance
Historical ComparisonAbout MOGU MOGU Inc.
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.